IPO for Prelude Therapeutics (PRLD) Paused on Volatility After Ramp Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Prelude Therapeutics (PRLD) IPO Opens 33% Higher
September 25, 2020 11:46 AM EDTToday's IPO for Prelude Therapeutics Incorporated (NASDAQ: PRLD) opened for trading at $25.23 after pricing its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share.
In addition, Prelude Therapeutics has granted the underwriters a 30-day option... More
Prelude Therapeutics Inc. (PRLD) Prices 8.325M Share IPO at $19/Sh
September 25, 2020 6:17 AM EDTPrelude Therapeutics Incorporated (NASDAQ: PRLD) today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Prelude, before deducting underwriting commissions and offering expenses, are expected to be... More
